#China #Hong Kong #Akeso #Ivonescimab #biliary tract cancer

Akeso's Ivonescimab Receives Fifth Breakthrough Therapy Designation

In a remarkable achievement, Akeso, Inc. has announced that its innovative bispecific antibody, Ivonescimab, has received its fifth Breakthrough Therapy Designation from the National Medical Products Administration (NMPA) in China. This designation particularly pertains to the use of Ivonescimab in combination with chemotherapy for first-line treatment of advanced biliary tract cancer (BTC). This latest approval illustrates the drug's expanding clinical significance and its potential to serve patients facing challenging cancer diagnoses.

Significance of the Breakthrough Therapy Designation

The Breakthrough Therapy Designation is awarded for treatments that provide significant benefits over existing therapies. It boosts the development speed by facilitating more efficient regulatory interactions and providing intensified guidance throughout the process. Grasping this commendation illustrates the increasing recognition of Ivonescimab from regulatory bodies and underlines its importance in treating cancers characterized by high unmet medical needs.

Previously, Ivonescimab secured three designations for lung cancer and one for triple-negative breast cancer (TNBC). This notable recognition showcases a broader potential application across various malignancies, as it is increasingly becoming a critical contender in the biopharmaceutical landscape.

Clinical Trials and Promising Results

A robust clinical trial program is underway to substantiate Ivonescimab's efficacy. A multicenter, randomized Phase III study, named AK112-309/HARMONi-GI1, is actively investigating the combination of Ivonescimab and chemotherapy against standard therapy with durvalumab plus chemotherapy for patients with advanced BTC. The completion of patient enrollment signifies a strong commitment to evaluating the drug's potential.

Preliminary outcomes from a Phase 1b/II trial presented at the 2024 ASCO Annual Meeting further emphasize its promise. The combination therapy recorded an Objective Response Rate (ORR) of 63.6% and a remarkable Disease Control Rate (DCR) of 100%. Additionally, median Progression-Free Survival (mPFS) stood at 8.5 months, while median Overall Survival (mOS) was noted at 16.8 months. The compelling results from these earlier phases lay a robust groundwork for the ongoing registrational trial and validate the transformative potential of this treatment in a field where options are often limited.

Future Prospects and Commitment to Innovation

Akeso remains fervently committed to advancing innovative solutions in biopharmaceuticals. Established in 2012, the company has developed a robust ecosystem for research and development grounded in proprietary technologies, including its Tetrabody bispecific antibody platform.

With over 50 innovative assets in its pipeline, including 26 in clinical trials, Akeso’s inventive approach and commitment to addressing major diseases continue to position it as a leader in the global biopharmaceutical industry. The company’s effective integration of diverse resources persists as a catalyst for delivering first-in-class and best-in-class therapies that are affordable and positively impact patient lives worldwide.

As Akeso prepares to navigate the next stages of Ivonescimab's development, the anticipation surrounding its role in treating advanced biliary tract cancer grows, holding hopes for improved patient outcomes and a significant stride forward in cancer therapies.

For further updates on Akeso and its innovative solutions, visit their official website or connect on LinkedIn for real-time news and progress on their groundbreaking efforts in biotechnology.

• ---